Last update Aug. 20, 2022

إيزراديبين

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a dihydropyridine-type calcium channel blocker with actions similar to those of nifedipine. It is used in the treatment of hypertension. Oral administration twice daily.

At latest update no published data were found on excretion into breast milk.

Its high plasma protein binding capacity and very wide volume of distribution makes it highly unlikely a passage into breast milk.

Although it has a low oral bioavailability this may increase by 20% when administered with a meal, which would increase the oral absorption in the infant.

Evidence on other antihypertensive drugs of the same family with similar structure, pharmacokinetics and action profile (nifedipine, nimodipine, nicardipine) has shown that they are excreted into milk in non-significant amount.

Expert authors consider the use of this medication possible during breastfeeding. (Hale, Malachias 2016, Briggs 2015)

Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug should be used, especially during the neonatal period and/or in case of premature infants.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

إيزراديبين is Isradipine in Arabic.

Is written in other languages:

Group

إيزراديبين belongs to this group or family:

Tradenames

Main tradenames from several countries containing إيزراديبين in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 15 - 24 %
Molecular weight 371 daltons
Protein Binding 95 %
VD 3.9 l/Kg
pKa 16.95 -
Tmax 2 - 7 hours
8.4 hours

References

  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from https://www.halesmeds.com Consulted on April 10, 2024 Full text (link to original source)
  2. Malachias MV, Figueiredo CE, Sass N, Antonello IC, Torloni MR, Bortolotto MRF L. 7th Brazilian Guideline of Arterial Hypertension: Chapter 9 - Arterial Hypertension in pregnancy Arq Bras Cardiol. 2016 Abstract Full text (link to original source) Full text (in our servers)
  3. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  4. Novartis. Isradipine. Product Monograph. 2014 Full text (in our servers)
  5. Novartis. Ficha técnica. Isradipino. 2008 Full text (in our servers)

Total visits

1,582

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM